Angiogenic Factors: Molecular Classes, Regulatory Mechanisms, and Experimental as Well as Translational Applications
Angiogenic Factors: Molecular Classes, Regulatory Mechanisms, and Experimental as Well as Translational Applications
Angiogenesis is the process by which new microvessels form from an existing vascular network. It is jointly regulated by soluble pro-angiogenic and anti-angiogenic factors, cytokines, protease systems, extracellular matrix (ECM) components, and adhesion molecules. Angiogenesis is physiologically indispensable for embryonic development, tissue repair, and regeneration; however, it is frequently dysregulated in pathological contexts such as tumor progression, diabetic complications, chronic inflammation, and retinal neovascular disorders. Defining the principal signaling axes of key angiogenic factors and their network-level interactions provides a foundation for building reliable detection strategies, in vitro and in vivo models, drug-screening platforms, and targeted intervention approaches.
Keywords: angiogenesis; endothelial cells; VEGF; FGF; angiopoietin; Notch; extracellular matrix; anti-angiogenic therapy; tissue repair
I. Concepts and the Scope of Angiogenic Factors
1.1 Boundaries between angiogenesis and related concepts
Angiogenesis typically refers to the formation of new vessels from pre-existing vasculature through endothelial activation, migration, and sprouting. Related concepts that should be distinguished include:
(1) Vasculogenesis: predominantly observed during embryogenesis, in which endothelial progenitors or vascular precursor cells form a primary vascular plexus in situ.
(2) Arteriogenesis: primarily involves the enlargement and remodeling of pre-existing collateral vessels, strongly driven by shear stress, and more prominently reflects contributions from mural cells and immune cells.
(3) Vascular maturation and stabilization: staged events including pericyte/smooth muscle cell recruitment, basement membrane reconstruction, and restoration of vascular permeability control.
1.2 Definition and functional categories of angiogenic factors
“Angiogenic factors” do not constitute a single molecular family; rather, the term denotes a functional set of molecules with pro-angiogenic or anti-angiogenic activity, mainly including:
(1) Pro-angiogenic factors: promote endothelial proliferation, migration, survival, lumen formation, and changes in vascular permeability.
(2) Anti-angiogenic factors: suppress endothelial activation or block essential receptor signaling to maintain vascular quiescence.
(3) Stabilization/maturation factors: enhance pericyte coverage and vascular wall organization, reduce leakage, and improve perfusion efficiency.
II. Key Angiogenic Factors and Signaling Pathways
2.1 The VEGF family and the VEGFR axis
VEGF (vascular endothelial growth factor) is among the most central pro-angiogenic factors, typically signaling through VEGFR-1/2/3.
(1) VEGF-A: the canonical pro-angiogenic factor, primarily acting via VEGFR-2 to activate MAPK/ERK, PI3K/AKT, and PLCγ-PKC pathways, thereby promoting endothelial proliferation, migration, and survival, while markedly increasing vascular permeability.
(2) VEGF-B: more closely linked to endothelial survival and metabolic coupling; its pro-angiogenic effects are comparatively modest and context-dependent.
(3) VEGF-C/VEGF-D: key drivers of lymphangiogenesis mainly through VEGFR-3, and can also influence angiogenesis under specific conditions.
(4) PlGF: associated with VEGFR-1; often amplifies angiogenic signaling and modulates monocyte/macrophage recruitment in inflammatory and tumor microenvironments.
The VEGF/VEGFR axis occupies a hub position in tumor neovascularization, retinal/choroidal neovascularization, and ischemic tissue repair.
2.2 The FGF family and FGFR signaling
Within the FGF (fibroblast growth factor) family, FGF2 (bFGF) is most widely studied in angiogenesis.
(1) FGF2 directly promotes endothelial proliferation and migration, and enhances sprouting and lumen formation by inducing MMP expression and modulating ECM degradation and remodeling.
(2) FGF signaling frequently compensates for VEGF pathway inhibition, contributing to anti-VEGF resistance, tissue repair angiogenesis, and angiogenesis in chronic inflammation.
(3) Binding of FGF to heparin/heparan sulfate proteoglycans (HSPGs) supports its storage and localized presentation within the ECM, shaping spatial gradients and bioavailability.
2.3 The angiopoietin/Tie2 axis and vascular stabilization
Angiopoietins (Angs) regulate vessel maturation and stabilization through Tie2, and also participate in vascular remodeling under inflammatory conditions.
(1) Ang1: generally promotes vascular stabilization, pericyte coverage, and barrier maintenance, thereby reducing leakage.
(2) Ang2: often viewed as a context-dependent destabilizing factor; it facilitates sprouting and remodeling when VEGF is sufficient, but may promote regression when VEGF is limiting. In inflammatory and tumor microenvironments, Ang2 is frequently associated with aberrant vascular architecture.
The Tie2 axis provides a mechanistic basis for “vascular normalization” strategies and is commonly incorporated into integrated intervention frameworks together with the VEGF axis.
2.4 PDGF, TGF-β, and pericyte recruitment
(1) PDGF-B/PDGFR-β: essential for pericyte recruitment and vessel wall stabilization; its loss can render nascent vessels fragile, increase leakage, and reduce perfusion.
(2) TGF-β: exhibits biphasic effects depending on receptor complexes and dose context; it can promote ECM deposition and vascular maturation, but can also suppress endothelial proliferation and drive fibrosis-associated remodeling. Its roles in tumors and chronic injury are strongly context-specific.
2.5 Developmental pathways (Notch/Dll4, Wnt, Shh) in sprouting selection
(1) Notch/Dll4: controls tip/stalk cell fate, thereby determining sprout number and branch density; it is a key module governing the “structural quality” of vascular networks.
(2) Wnt and Shh: contribute to vasculogenesis and barrier-property establishment in specific tissues (e.g., CNS vasculature and organogenesis) and interact with VEGF and Ang signaling.
2.6 Network amplification by cytokines, chemokines, and protease systems
(1) Inflammatory cytokines: IL-1β and TNF-α can induce VEGF, Ang2, and MMP expression, linking inflammation to angiogenesis.
(2) Chemokines: the CXCL12/CXCR4 axis influences endothelial progenitor recruitment and vascular repair.
(3) Protease systems: MMP2/MMP9 degrade basement membrane and release matrix-sequestered growth factors, generating a microenvironment permissive for sprouting.
(4) Adhesion and matrix signaling: integrins (e.g., αvβ3, α5β1) mediate cell–matrix mechanochemical coupling and synergize with growth factor receptor signaling, thereby shaping migration efficiency and lumen formation.
III. A Stage-Based Mechanistic Framework of Angiogenesis
3.1 Endothelial activation and basement membrane remodeling
(1) Hypoxia and HIF signaling upregulate VEGF and other pro-angiogenic factors, relieving quiescence.
(2) MMPs drive focal basement membrane degradation, exposing adhesion sites and releasing matrix-bound factors.
(3) Endothelial polarity is established, and tip cells emerge to guide the leading edge.
3.2 Sprouting, migration, and branch patterning
(1) Tip cells sense VEGF gradients, extend filopodia, and steer directionality.
(2) Stalk cell proliferation and lumen formation drive vessel elongation.
(3) Notch/Dll4 regulates sprout number to prevent excessive branching that would compromise effective perfusion.
3.3 Anastomosis, perfusion, and maturation/stabilization
(1) Anastomosis establishes circulation; shear stress and flow stimulate structural remodeling.
(2) PDGF-B promotes pericyte coverage, while Ang1/Tie2 supports barrier function and anti-leakage capacity.
(3) Basement membrane redeposition and ECM reconstruction enhance long-term stability.
IV. Experimental Research and Detection Applications of Angiogenic Factors
4.1 Molecular- and protein-level detection strategies
(1) Gene expression and pathway readouts
① RT-qPCR for transcript quantification of VEGF-A, FGF2, ANGPT1/2, PDGFB, MMP9, and related genes.
② RNA in situ hybridization to build spatial expression maps, particularly for microregional tissue analyses.
(2) Protein quantification and localization
① ELISA and multiplex immunoassays for quantifying VEGF, FGF2, Ang2, and others in serum/plasma, tissue lysates, or conditioned media.
② Western blot for receptor phosphorylation (e.g., p-VEGFR2) and downstream signaling readouts (e.g., p-AKT, p-ERK).
③ Immunohistochemistry/immunofluorescence for CD31, VE-cadherin, α-SMA, NG2 and related markers to assess vessel density, maturity, and pericyte coverage.
Methodologically, recombinant VEGF-A165 and recombinant FGF2 are commonly included as positive stimulation controls to verify assay sensitivity and inter-batch consistency.
4.2 In vitro functional assay platforms
(1) Endothelial proliferation and migration
① EdU incorporation or Ki67 staining for proliferation assessment.
② Scratch-wound assays and Transwell migration assays for migratory capacity.
(2) Lumen formation and three-dimensional sprouting
① Matrigel tube formation assays for rapid comparison of pro-angiogenic effects.
② Spheroid sprouting and 3D hydrogel models more closely approximate physiological sprouting and are suitable for studying Notch, MMPs, and matrix mechanics.
(3) Permeability and barrier function
① TEER measurements or fluorescent tracer leakage assays to evaluate VEGF-induced permeability changes and Ang1-mediated stabilization effects.
4.3 In vivo and organoid-based models
(1) Chicken chorioallantoic membrane (CAM) assays for rapid angiogenesis evaluation and pharmacological screening.
(2) Matrigel plug assays for in vivo pro-angiogenic/anti-angiogenic efficacy testing.
(3) Ischemia models (e.g., hindlimb ischemia, myocardial ischemia) for reparative angiogenesis.
(4) Tumor xenograft or orthotopic tumor models for studying abnormal tumor vasculature, leakage, and treatment responses.
(5) Organoid–vasculature co-culture systems to investigate tissue-specific angiogenesis and barrier features, with relevance to drug transport and toxicology.
V. Translational and Application Scenarios of Angiogenic Factors
5.1 Anti-angiogenic therapy and vascular normalization
(1) Oncology
Anti-VEGF/VEGFR strategies suppress angiogenic driving signals, limiting tumor blood supply and reshaping the microenvironment. In some frameworks, emphasis is placed on “vascular normalization,” whereby reduced leakage, improved perfusion, and enhanced immune-cell infiltration increase synergy with radiotherapy, chemotherapy, or immunotherapy. Targets involving Ang2/Tie2, PDGF, and Notch are frequently explored for combination strategies and resistance mechanisms.
(2) Ocular neovascular diseases
Retinal/choroidal neovascularization is highly dependent on the VEGF axis, making VEGF inhibition a central approach in both clinical and research settings. In relapse or incomplete response, inflammatory mediators and Ang2 and other network components often require evaluation.
5.2 Pro-angiogenic therapy and tissue repair
(1) Repair of ischemic diseases
In hindlimb or myocardial ischemia, pro-angiogenic strategies aim to improve perfusion and metabolic supply. VEGF-A, FGF2, and CXCL12 and their delivery formats (protein, gene, extracellular vesicles, or controlled-release materials) represent common research pathways.
(2) Wound healing and regenerative medicine
Chronic diabetic wounds are often characterized by endothelial dysfunction, persistent inflammation, and abnormal matrix remodeling. Rebalancing VEGF, FGF, TGF-β, and MMP activity, while promoting pericyte recruitment and basement membrane reconstruction, can improve neovessel quality and shorten healing time.
(3) Tissue engineering and biomaterials
Incorporating recombinant VEGF-A165 and recombinant FGF2 into collagen, gelatin methacryloyl (GelMA), hyaluronic acid, and related hydrogels to generate local gradients and controlled release can mitigate oxygen diffusion limitations and support cell survival in thick engineered tissues.
5.3 Biomarkers and companion diagnostics
(1) Disease stratification and prognosis
Plasma/serum VEGF, Ang2, and inflammatory cytokine panels can reflect angiogenic activation and endothelial stress states, supporting stratification and response-monitoring frameworks.
(2) Treatment response and resistance indications
In anti-VEGF therapy, Ang2 upregulation, FGF pathway compensation, or intensified inflammatory networks may indicate emerging resistance. Combining multi-analyte profiling with imaging-derived metrics can improve interpretability.
VI. Experimental Design and Cause Analysis of Common Issues
6.1 Common causes of weak pro-angiogenic effects
(1) Cell state and passage-related factors: excessive passaging, inappropriate cell density, or serum lot variation can substantially alter proliferation and tube formation readouts.
(2) Reduced bioactivity of factors: repeated freeze–thaw cycles, adsorption loss, incorrect buffer systems, or pH deviations can reduce effective concentration.
(3) Mismatched matrix conditions: Matrigel lot variability, gelation time, temperature control, and coating thickness influence network morphology and reproducibility.
6.2 Common causes of variability in anti-angiogenic results
(1) Insufficient interpretability with single metrics: relying solely on a single readout such as tube length/branch number can confound cytotoxicity, migration inhibition, and permeability effects.
(2) Uncontrolled network compensation: after VEGF-axis inhibition, alternative pathways such as FGF or Ang2 can be activated, yielding discordant short- versus long-term outcomes.
(3) In vivo heterogeneity: differences in matrix composition, immune infiltration, and hypoxia across tumor models can markedly shift angiogenesis dependence.
6.3 Recommended QC and readout combinations
(1) In vitro: proliferation (EdU/Ki67) + migration (Transwell) + tube formation (Matrigel/3D sprouting) + phosphorylation readouts (p-VEGFR2/p-AKT/p-ERK).
(2) In vivo: vessel density (CD31) + maturity (α-SMA/NG2 pericyte coverage) + permeability (tracer leakage) + perfusion (perfusion markers or functional imaging).
(3) Controls: recombinant VEGF-A165 or recombinant FGF2 as positive controls; VEGFR inhibitors or anti-VEGF strategies as inhibition controls, to define assay dynamic range and inter-batch consistency.
VII. Aladdin-Related Products
Pathway Module | Product Name | Catalog No. | Grade and Purity | Application Positioning |
VEGF/VEGFR | Ranibizumab (anti-VEGFA) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | VEGF-A functional blocking control; used to inhibit pro-angiogenic responses and validate VEGF-axis contribution | |
VEGF/VEGFR | Ramucirumab (anti-VEGFR2) | Carrier Free, Recombinant, ExactAb™, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | VEGFR2 pathway blocking control; used to confirm VEGF signaling dependence and pharmacodynamic readouts | |
VEGF/VEGFR | Recombinant Human VEGF 165 GMP Protein | ActiBioPure™, Bioactive, GMP, Animal Free, Carrier Free, High performance, ≥97%(SDS-PAGE&SEC-HPLC) | Pro-angiogenic positive stimulus; used to standardize endothelial proliferation/migration/tube formation assays | |
VEGF/VEGFR | Recombinant Human VEGF 165 Protein | ActiBioPure™, GMP, Animal Free, Carrier Free, Bioactive, High Performance, sterile, ≥98%(SDS-PAGE), His Tag | VEGF-A165 stimulation; used to build dose–response curves and signaling readouts (p-AKT/p-ERK) | |
VEGF/VEGFR | Recombinant Human VEGF Protein | GMP, Bioactive, ActiBioPure™, High performance, Animal Free, Carrier Free, ≥95%(SDS-PAGE) | VEGF stimulation control; positive control for angiogenesis functional assays and lot-to-lot consistency verification | |
VEGF/VEGFR | Recombinant Human VEGFA-165 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, High Performance, See COA | VEGFA stimulation; used in endothelial migration/sprouting/tube formation models and pathway activation validation | |
VEGF/VEGFR | Recombinant Human VEGFR2/KDR Protein | Animal Free, Carrier Free, ActiBioPure™, Bioactive, High performance, ≥95%(SDS-PAGE) | Ligand–receptor binding system setup; used for competition binding and mechanism validation study designs | |
VEGF/VEGFR | Recombinant Human VEGFR3/Flt-4 Protein | Animal Free, Carrier Free, ≥95%(SDS-PAGE) | VEGFR3-supporting reagent; receptor-side validation and system setup for VEGF-C/D direction | |
VEGF/VEGFR | Recombinant VEGF Receptor 2 Antibody | Recombinant, ExactAb™, Validated, See COA | VEGFR2 detection and mechanism validation; used to assess receptor expression and post-intervention changes | |
VEGF/VEGFR | Recombinant VEGF Receptor 2 Antibody | ExactAb™, Validated, Recombinant, 0.12 mg/mL | VEGFR2 detection; used for receptor-level evaluation and pathway experiment support | |
VEGF/VEGFR | Recombinant VEGFA Antibody | ExactAb™, Validated, Carrier Free, Recombinant, 0.075 mg/mL | VEGFA detection; used to verify VEGF changes in supernatants/samples and support pathway association analysis | |
VEGF/VEGFR | Recombinant VEGF Receptor 1 Antibody | See COA | VEGFR1 detection support; used for receptor-side validation in the PlGF–VEGFR1 module | |
VEGF/VEGFR | Recombinant VEGF Receptor 1 Antibody | ExactAb™, Validated, Recombinant, 0.1 mg/mL | VEGFR1 detection and mechanism validation; used for receptor expression and signaling association assessment | |
VEGF/VEGFR | Recombinant Human PLGF Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥97%(SDS-PAGE&HPLC) | PlGF stimulant; used to model enhanced pro-angiogenic signaling under inflammatory/tumor-like contexts | |
VEGF/VEGFR | Recombinant Human PlGF Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE) | PlGF stimulation control; supplemental stimulation condition for migration/tube formation functional readouts | |
VEGF/VEGFR | Recombinant Human PlGF Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, ≥90%(SDS-PAGE), See COA | PlGF stimulation control; used for pathway compensation and synergy mechanism validation | |
VEGF/VEGFR | PLGF Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, See COA | PlGF detection support; used to verify PlGF level changes under stimulation/blockade conditions | |
VEGF/VEGFR | PLGF Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, See COA | PlGF detection support; used as control and for repeat validation in mechanistic studies | |
VEGF/VEGFR | AAL 993 | ≥98% | VEGFR inhibition control; used to block pro-angiogenic signaling and validate pathway dependence | |
VEGF/VEGFR | AEE788 (NVP-AEE788) | ≥97% | Parallel RTK inhibition control; used to test pathway crosstalk and contribution of alternative pathways | |
FGF/FGFR | Recombinant Human FGF basic/FGF2 Protein | ActiBioPure™, Carrier Free, High Performance, Bioactive, ≥90%(SDS-PAGE), See COA | FGF2 stimulant; used for proliferation/migration/sprouting models and VEGF-compensation mechanism studies | |
FGF/FGFR | Recombinant Human FGF basic/FGF2/bFGF GMP Protein | Animal Free, Carrier Free, GMP, Bioactive, ActiBioPure™, High performance, ≥97%(SDS-PAGE&SEC-HPLC) | High-consistency FGF2 stimulus; used for culture system and screening platform standardization | |
FGF/FGFR | Recombinant Human FGF basic/FGF2/bFGF Protein | Carrier Free, GMP, Bioactive, ActiBioPure™, High Performance, Animal Free, ≥95%(SDS-PAGE) | FGF2 stimulation control; used to validate FGF-axis dependence and tolerance/compensation mechanisms | |
FGF/FGFR | Recombinant FGF2 Antibody | Recombinant, ExactAb™, Validated, See COA | FGF2 detection and mechanism validation; used to assess FGF2 changes in supernatants/tissue samples | |
FGF/FGFR | Recombinant FGF2 Antibody | ExactAb™, Validated, Recombinant, High performance, 0.103 mg/mL | FGF2 detection support; strengthens evidence for pathway crosstalk and compensation mechanisms | |
FGF/FGFR | AZD4547 | Moligand™, ≥99% | FGFR inhibition control; used for FGF-axis dependence and tolerance/compensation validation | |
FGF/FGFR | BGJ398 (NVP-BGJ398) | Moligand™, ≥98% | FGFR inhibition control; suitable for efficacy validation and signal regression experiments | |
FGF/FGFR | LY2874455 | Moligand™, ≥99% | Broad-spectrum FGFR inhibition control; used to suppress FGF compensatory pathways and assess phenotype reversal | |
Ang/Tie2 | Recombinant Angiopoietin 1 Antibody | Recombinant, ExactAb™, Validated, See COA | Ang1-related detection; used for mechanistic readouts in vascular stabilization/barrier maintenance | |
Ang/Tie2 | Recombinant Angiopoietin 2/ANG2 Antibody | ExactAb™, Validated, Recombinant, High performance, 0.7 mg/mL | Ang2-related detection; used for vascular destabilization/remodeling studies under inflammatory/tumor contexts | |
Ang/Tie2 | Regeneron patent anti-TIE-2 (anti-TIE2) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | Tie2 receptor-side blockade/mechanism validation; supports stabilization and normalization-related readouts | |
Ang/Tie2 | AMG-Tie2-1 | Moligand™, 10 mM in DMSO | Tie2 inhibition control; used to block Ang/Tie2 signaling and evaluate stabilization/permeability/maturation readouts | |
Ang/Tie2 | BAY 826 | ≥98%(HPLC) | Tie2 pathway inhibition control; used to validate Ang1/Ang2 dependence and Tie2 contribution to vascular remodeling | |
Ang/Tie2 | Tie2 kinase inhibitor 3 | -- | Tie2 kinase tool compound; used to validate Tie2 downstream signaling and phenotype regression | |
Ang/Tie2 | Tie2 kinase inhibitor | Moligand™, 10mM in DMSO | Tie2 inhibition control; used for Ang/Tie2 blockade and combination strategy evaluation | |
PDGF/PDGFR | Recombinant Human PDGF AA Protein | Carrier Free, Bioactive, ActiBioPure™, High Performance, ≥95%(SDS-PAGE), See COA | PDGF-AA stimulation; used to validate PDGFRα-side signaling and pericyte/stroma-related effects | |
PDGF/PDGFR | Recombinant Human PDGF-AB Protein | Carrier Free,Bioactive,ActiBioPure™,High Performance,≥95%(SDS-PAGE),See COA | PDGF-AB stimulation; used to establish dose–response and maturity/co-culture readout systems | |
PDGF/PDGFR | Recombinant Human PDGF-AB Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,≥95%(SDS-PAGE),See COA | PDGF-AB stimulation control; used for animal-free systems and platform standardization | |
PDGF/PDGFR | Recombinant Human PDGF-BB GMP Protein | Animal Free, Carrier Free, GMP, Bioactive, ActiBioPure™, High performance, ≥75%(SDS-PAGE&SEC-HPLC) | High-consistency PDGF-BB stimulation; used to standardize pericyte recruitment/maturation platforms | |
PDGF/PDGFR | Recombinant Human PDGF-BB Protein | Carrier Free, Bioactive, ActiBioPure™, High Performance, ≥95%(SDS-PAGE), See COA | PDGF-BB positive control; used to validate pericyte recruitment and vascular maturation readouts | |
PDGF/PDGFR | Recombinant Rat PDGF-BB Protein | Carrier Free,Bioactive,ActiBioPure™,≥95%(SDS-PAGE),See COA | Rat PDGF-BB stimulation; supporting mechanistic/efficacy validation in rat models | |
PDGF/PDGFR | Recombinant Human PDGFC Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE) | PDGF-C stimulation; used to study context-dependent PDGF-family effects and remodeling contribution | |
PDGF/PDGFR | Recombinant Human PDGF R alpha Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, ≥95%(SDS-PAGE) | PDGFRα receptor-side tool protein; used for binding/competition and mechanistic validation | |
PDGF/PDGFR | Recombinant Human PDGF R beta Protein | Animal Free, Carrier Free, ≥95%(SDS-PAGE) | PDGFRβ receptor-side tool protein; used for receptor-side validation and system setup of the pericyte recruitment axis | |
PDGF/PDGFR | Recombinant Human PDGFR alpha Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE) | PDGFRα receptor-side tool protein; used for animal-free systems and mechanism validation | |
PDGF/PDGFR | IMC-2C5 (anti-PDGFRB/CD140B) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | PDGFRβ receptor-side blockade/mechanism validation; attribution of pericyte recruitment and maturation readouts | |
PDGF/PDGFR | Recombinant PDGF B Antibody | Recombinant, ExactAb™, Validated, See COA | PDGF-B detection; used to assess PDGF-B changes in samples and strengthen mechanistic evidence | |
PDGF/PDGFR | Recombinant PDGFR alpha Antibody | ExactAb™, Validated, Recombinant, 0.3 mg/mL | PDGFRα detection; used to evaluate receptor expression profiles and post-intervention changes | |
PDGF/PDGFR | Recombinant PDGFR beta Antibody | ExactAb™, Validated, Recombinant, 0.3 mg/mL | PDGFRβ detection; used for receptor-level evaluation in pericyte-related pathways and pathway verification | |
PDGF/PDGFR | AC 710 | Moligand™, ≥98% | PDGFR inhibition control; used to validate PDGF/PDGFR contribution to pericyte recruitment and vascular stabilization | |
PDGF/PDGFR | AG-370 | ≥99% | PDGFR inhibition control; used to block PDGF-driven pericyte/smooth muscle signaling input | |
PDGF/PDGFR | CP-673451 | Moligand™, ≥98% | Pharmacological PDGFR intervention; used for pericyte recruitment mechanism validation and phenotype regression | |
PDGF/PDGFR | DCC-2618 | ≥98% | Parallel PDGFR + c-Kit inhibition control; used for mechanism/efficacy validation in microenvironment-involved models | |
PDGF/PDGFR | JNJ-10198409 | ≥98% | PDGF-BB-related pathway inhibition control; used for maturity/leakiness/perfusion phenotype regression validation | |
PDGF/PDGFR | KG 5 | ≥98%(HPLC) | Multi-target parallel inhibition control; used to assess network crosstalk and alternative pathway involvement | |
PDGF/PDGFR | SU 16f | ≥98%(HPLC) | PDGFRβ inhibition control; used for causal validation of the pericyte recruitment–vascular maturation axis | |
PDGF/PDGFR | SU4312 | Moligand™, ≥98% | VEGFR/PDGFR parallel inhibition control; used to validate coupled contributions of VEGF and PDGF axes | |
PDGF/PDGFR | TSU-68 (SU6668, Orantinib) | Moligand™, ≥98% | PDGFR inhibition control; used to evaluate in vitro/in vivo angiogenesis inhibition and remodeling readouts | |
PDGF/PDGFR | Pdgfra Mouse Pre-designed siRNA Set A | -- | Gene-level PDGFRα intervention; used for receptor-side causal validation and pathway attribution | |
PDGF/PDGFR | Pdgfrb Mouse Pre-designed siRNA Set A | -- | Gene-level PDGFRβ intervention; used for pericyte recruitment/maturation mechanism validation | |
PDGF/PDGFR | Pdgfrb Rat Pre-designed siRNA Set A | -- | Rat PDGFRβ gene-level intervention; used for mechanistic validation in rat systems | |
TGF-β/TGFBR | Recombinant Human TGF-beta 1 GMP Protein | ActiBioPure™, Bioactive, GMP, Animal Free, Carrier Free, High performance, ≥97%(SDS-PAGE&SEC-HPLC) | High-consistency TGF-β1 stimulation; used to standardize TGF-β-driven remodeling/maturation readout systems | |
TGF-β/TGFBR | Recombinant Human TGF-beta 1 Monomer Protein | ActiBioPure™, Bioactive, Carrier Free, ≥95%(SDS-PAGE) | TGF-β1 stimulation; used for signaling kinetics and dose–response readouts (e.g., p-Smad2/3) | |
TGF-β/TGFBR | Recombinant Human TGF-beta 1 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, High performance, ≥95%(SDS-PAGE) | TGF-β1 stimulation; used to build contextual models for matrix deposition and maturation changes | |
TGF-β/TGFBR | Recombinant Human TGF-beta 1 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, ≥95%(SDS-PAGE), See COA | TGF-β1 stimulation control; used in carrier-free systems and multi-factor co-stimulation settings | |
TGF-β/TGFBR | Recombinant Human TGF beta 2 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, ≥95%(SDS-PAGE) | TGF-β2 stimulation control; used for system standardization and lot-to-lot consistency | |
TGF-β/TGFBR | Recombinant Mouse TGF-beta 1 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE) | Mouse TGF-β1 stimulation; used for mouse-model supporting validation | |
TGF-β/TGFBR | Recombinant Mouse TGF-beta 2 Protein | ActiBioPure™, Bioactive, Animal Free, Carrier Free, High performance, ≥95%(SDS-PAGE) | Mouse TGF-β2 stimulation; used for mouse-model supporting validation | |
TGF-β/TGFBR | Recombinant Human TGF-beta RIII Protein | Animal Free, Carrier Free, ≥90%(SDS-PAGE) | TGFBR3 receptor-side tool protein; used for binding/competition and receptor-side mechanism validation | |
TGF-β/TGFBR | Recombinant Mouse TGF-beta RII Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, High performance, ≥95%(SDS-PAGE) | Mouse TGFBR2 receptor-side tool protein; used for receptor-side mechanism studies | |
TGF-β/TGFBR | Fresolimumab (anti-TGFb1) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | TGF-β1 functional blocking control; used to validate TGF-β contribution to vascular remodeling/maturation and matrix deposition | |
TGF-β/TGFBR | Metelimumab (anti-TGFb1) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | TGF-β1 functional blocking control; used for repeat validation and cross-confirmation | |
TGF-β/TGFBR | NIS-793 (anti-TGFb1) | Carrier Free, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | TGF-β1 blockade control; used for mechanistic and pharmacodynamic readouts under tumor/chronic-injury contexts | |
TGF-β/TGFBR | SRK181 (anti-TGFb1) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | TGF-β1 blockade control; used for mechanism validation and evidence-chain reinforcement | |
TGF-β/TGFBR | Livmoniplimab (anti-LRRC32/TGFβ1) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | TGF-β accessibility/presentation-related blockade control; used to validate TGF-β regulation in microenvironment contexts | |
TGF-β/TGFBR | LY3022859 (anti-TGFBR2) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | TGFBR2 receptor-side blocking tool antibody; used for receptor-side mechanism validation | |
TGF-β/TGFBR | Recombinant TGF beta 1 Antibody | ExactAb™, Validated, Recombinant, 0.6 mg/mL | TGF-β1 detection; used to assess TGF-β changes in samples and support pathway association analysis | |
TGF-β/TGFBR | Recombinant TGF beta Receptor II Antibody | ExactAb™, Validated, Recombinant, 2.0 mg/mL | TGFBR2 detection; used to evaluate receptor expression and post-intervention changes | |
TGF-β/TGFBR | TGF beta Receptor I Antibody | ExactAb™, Validated, 1.0 mg/mL | TGFBR1 detection; used to evaluate receptor expression profiles and verify pathway relevance | |
TGF-β/TGFBR | TGF beta Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, ≥95%(SDS-PAGE), See COA | Mouse-system TGF-β detection/mechanism validation support | |
TGF-β/TGFBR | GW788388 | ≥98% | TGFBR1/ALK5 inhibition control; used to block receptor-side signaling and evaluate phenotype reversal | |
TGF-β/TGFBR | IN 1130 | ≥98%(HPLC) | TGFBR1 inhibition control; used for p-Smad2/3 and other mechanistic attribution readouts | |
TGF-β/TGFBR | ITD-1 | ≥98% | TGF-β pathway inhibition control; used for functional attribution of TGF-β-related remodeling outputs | |
TGF-β/TGFBR | LY2157299 | Moligand™, ≥99% | TGFBR1 inhibition control; used to validate coupling of vascular remodeling and fibrosis in tumor/chronic-injury contexts | |
TGF-β/TGFBR | LY364947 | Moligand™, ≥98% | TGFBR1 inhibition control; used to validate receptor kinase activity contribution to remodeling readouts | |
TGF-β/TGFBR | R 268712 | ≥98%(HPLC) | TGFBR1 inhibition control; used for receptor-side blockade and phenotype regression validation | |
TGF-β/TGFBR | RepSox | ≥98% | TGFBR1 inhibition control; used for receptor-kinase blockade and mechanism validation | |
TGF-β/TGFBR | SB525334 | ≥98% | TGFBR1 inhibition control; used for TGF-β/Smad pathway inhibition and interaction analysis | |
TGF-β/TGFBR | SD-208 | Moligand™, ≥98% | TGF-β-driven remodeling/maturation change mechanism validation | |
TGF-β/TGFBR | SM 16 | ≥98%(HPLC) | In vitro/in vivo pharmacodynamics and mechanism validation tool | |
TGF-β/TGFBR | NG25 | Moligand™, ≥98% | Node inhibition control for TGF-β–inflammation coupling; used for non-Smad branch mechanism validation | |
TGF-β/TGFBR | Recombinant Human CTGF Protein | Carrier Free, Azide Free, ≥90%(SDS-PAGE) | CTGF stimulation; used to enhance TGF-β downstream matrix remodeling conditions and validate vascular quality readouts | |
TGF-β/TGFBR | Recombinant Human CTGF/CCN2 Protein | Carrier Free, ≥85%(SDS-PAGE), See COA | CTGF stimulation control; used for matrix/fibrosis-like microenvironment and vascular remodeling association studies | |
TGF-β/TGFBR | Recombinant CTGF Antibody | Recombinant, ExactAb™, Validated, See COA | CTGF detection; used to assess TGF-β downstream matrix output and strengthen mechanistic evidence | |
Notch/Dll4 | DLL4 Human Pre-designed siRNA Set A | -- | DLL4 gene-level intervention; used for causal validation and attribution of sprouting-structure readouts in the Notch/Dll4 module | |
Notch/Dll4 | Recombinant Human DLL4 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, ≥95%(SDS-PAGE) | DLL4 ligand tool; used to activate Notch signaling and validate tip/stalk fate-regulation mechanisms | |
Notch/Dll4 | Demcizumab (anti-DLL4) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | DLL4 functional blocking control; used to modulate Notch/Dll4-mediated sprout number and branch density | |
Notch/Dll4 | Enoticumab (anti-DLL4) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | DLL4 blocking control; used for mechanism validation in Notch/Dll4 structural quality-control studies | |
Notch/Dll4 | Navicixizumab (anti-DLL4) | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | DLL4 blocking control; supports structured readouts in in vitro 3D sprouting and in vivo vascular network assays | |
MMP/ADAM-17 | GM 6001 | Moligand™, ≥98% | Inhibits matrix degradation and sprouting microenvironment formation; used to validate MMP involvement in sprouting/migration dependence | |
MMP/ADAM-17 | NNGH | ≥98% | MMP inhibition control; used for mechanistic attribution of tube formation and migration readouts | |
MMP/ADAM-17 | PD 166793 | ≥99%(HPLC) | MMP inhibition control; used to suppress angiogenic phenotypes and define dynamic time windows | |
MMP/ADAM-17 | TAPI 2 | ≥95%(HPLC) | Inflammation mediator shedding and matrix-remodeling inhibition control; used for inflammation–angiogenesis coupling validation | |
ERK, JAK/STAT3 | ERK inhibitor | ≥95% | MAPK/ERK blockade control; used to validate downstream contribution to proliferation/migration/tube formation | |
ERK, JAK/STAT3 | FR 180204 | Moligand™, ≥98%(HPLC) | ERK blockade control; used for phenotype regression and signaling dependence validation | |
ERK, JAK/STAT3 | WP1066 | Moligand™, ≥98% | JAK/STAT3 blockade control; used to validate inflammation-driven pro-angiogenic transcriptional programs | |
ERK, JAK/STAT3 | S3I-201 | ≥96% | STAT3 blockade control; used for attribution of pro-angiogenic gene expression and functional phenotypes |
Angiogenic factors form a highly interactive regulatory network. Their biological effects depend not only on the abundance of individual molecules, but also on receptor expression programs, ECM-mediated presentation, inflammatory and hypoxic states, and the degree of vascular maturation. At the application level, anti-angiogenic and pro-angiogenic approaches are not simply oppositional; instead, they represent strategy-driven choices aligned with two distinct objectives: suppressing pathological and non-productive vasculature versus reconstructing high-quality perfused vessels. Integrative modeling of key axes (VEGF, FGF, Ang/Tie2, PDGF) together with developmental modules (Notch/Dll4) and matrix remodeling systems (MMPs, integrins), coupled to multidimensional readouts, can substantially improve experimental interpretability and the reliability of translational decision-making.
For more related articles, please see below:
[1] Fibroblast growth factor-induced angiogenesis model
[2] Comprehensive Overview of Vascular Endothelial Gth Factors (VEGF)
[3] The Fibroblast Development Factor (FGF) Family
[4] Regulation of TGF-beta activity by BMP-1
Aladdin: https://www.aladdinsci.com/